ResearcherUniversity of MinnesotaNo recent work listed
Edward W. Greeno
Matched on ORCID iD 0000-0002-9272-6161; OpenAlex author ID A5018503119. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4
- Trials
- 1
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper
Papers 4
- Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
- RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Co-author DOI 10.1016/j.molonc.2016.05.004↗
- A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally… Co-author DOI 10.1007/s00280-010-1383-0↗
- Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACO… Co-author DOI 10.1093/annonc/mdq384↗
Trials 1
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eileen Mary O'Reilly · 2 shared papers, 2011–2018 · strength 0.09
- Paper Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line… DOI 10.1007/s10637-018-0580-2↗
- Paper Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and inte… DOI 10.1093/annonc/mdq384↗
- Selwyn Maurice Vickers · 2 shared papers, 2011–2016 · strength 0.07
- Paper RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival … DOI 10.1016/j.molonc.2016.05.004↗
- Paper A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiose… DOI 10.1007/s00280-010-1383-0↗
- Donald J Buchsbaum · 2 shared papers, 2011–2016 · strength 0.07
- Paper RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival … DOI 10.1016/j.molonc.2016.05.004↗
- Paper A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiose… DOI 10.1007/s00280-010-1383-0↗
- John D. Christein · 2 shared papers, 2011–2016 · strength 0.07
- Paper RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival … DOI 10.1016/j.molonc.2016.05.004↗
- Paper A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiose… DOI 10.1007/s00280-010-1383-0↗
- James A. Posey · 2 shared papers, 2011–2016 · strength 0.07
- Paper RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival … DOI 10.1016/j.molonc.2016.05.004↗
- Paper A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiose… DOI 10.1007/s00280-010-1383-0↗
- Ashwin Reddy Sama · 1 shared paper, 2018 · strength 0.07
- Herbert I. Hurwitz · 1 shared paper, 2018 · strength 0.07
- Chris Verslype · 1 shared paper, 2018 · strength 0.07
- Manuel M. Hidalgo · 1 shared paper, 2018 · strength 0.07
- Chung‐Pin Li · 1 shared paper, 2018 · strength 0.07
- Vaibhav Sahai · 1 shared paper, 2018 · strength 0.07
- Johanna C. Bendell · 1 shared paper, 2018 · strength 0.07
- Kenneth H. Yu · 1 shared paper, 2018 · strength 0.07
- Eric Van Cutsem · 1 shared paper, 2018 · strength 0.07
- Teresa Mercade Macarulla · 1 shared paper, 2018 · strength 0.07
- Ryne C. Ramaker · 1 shared paper, 2016 · strength 0.05
- R Myers · 1 shared paper, 2016 · strength 0.05
- Martin J. Heslin · 1 shared paper, 2016 · strength 0.05
- Marie K. Kirby · 1 shared paper, 2016 · strength 0.05
- Sara J. Cooper · 1 shared paper, 2016 · strength 0.05
- Lalan S. Wilfong · 1 shared paper, 2011 · strength 0.02
- Ross Allen Abrams · 1 shared paper, 2011 · strength 0.02
- Mitchell C. Posner · 1 shared paper, 2011 · strength 0.02
- Peter W. T. Pisters · 1 shared paper, 2011 · strength 0.02
- Vincent J. Picozzi · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.